Table 1 Baseline characteristics of study participants (HIV-infected children) by randomized study arm assignment (N = 142)
Characteristic | Overall | Clinical & Immunologic(N = 71) | Clinical, Immunologic & Virologic (N = 71) | P value |
|---|---|---|---|---|
Study Site: n (%) | ||||
Mulago | 70 (49) | 35 (49) | 35 (49) | 1.000a |
Nsambya | 72 (51) | 36 (51) | 36 (51) | |
Age in years: Median (IQR) | 6 (5, 9) | 6 (5, 8) | 7 (5, 9) | 0.269b |
Sex: n (%) | 0.865a | |||
Female | 61 (43) | 31 (43) | 30 (42) | |
Male | 81 (57) | 40 (56) | 41 (58) | |
WHO Stage: n (%) | 0.947c | |||
1 | 22 (15) | 12 (17) | 10 (14) | |
2 | 57 (40) | 29 (41) | 28 (39) | |
3 | 54 (38) | 26 (37) | 28 (39) | |
4 | 9 (6) | 4 (6) | 5 (7) | |
NVP Exposure: n (%) | 0.938c | |||
Yes | 53 (37) | 27 (38) | 26 (37) | |
No | 76 (54) | 37 (52) | 39 (55) | |
Unknown | 13 (9) | 7 (10) | 6 (8) | |
In utero ART: n (%) | 0.960c | |||
Yes | 43 (30) | 21 (30) | 22 (31) | |
No | 82 (58) | 41 (58) | 41 (58) | |
Unknown | 17 (12) | 9 (12) | 8 (11) | |
HIV RNA copies/ml: n (%) | 0.722a | |||
≤ 1000 | 94 (66) | 46 (65) | 48 (68) | |
> 1000 | 48 (34) | 25 (35) | 23 (32) | |
HIV RNA copies/ml: n (%) | 1.000 a | |||
≤ 400 | 92 (65) | 46 (65) | 46 (65) | |
> 400 | 50 (35) | 25 (35) | 25 (35) | |
ART Duration in years: Median (IQR) | 4 (2, 5) | 3 (2, 4) | 4 (2, 5) | 0.225b |
CD cell count (%): Median (IQR) | 32 (26,38) | 33 (26, 38) | 32 (27, 38) | 0.931 b |
Absolute CD4 cell count: Median (IQR) | 1071 (759, 1416) | 1097 (776, 1537) | 1032 (721, 1326) | 0.501 b |
BMI-for-age Z: Median (IQR) | −0.26 (−0.92, 0.36) | −0.21 (−1.06, 0.43) | −0.28 (−0.88, 0.29) | 0.875 b |
Weight-for-age Z score: Median (IQR) | − 0.97 (− 1.54, − 0.25) | − 0.97 (− 1.37, − 0.33) | − 0.99 (− 1.63, − 0.15) | 0.933 b |
Height-for-age Z score: Median (IQR) | −1.07 (− 1.92, − 0.34) | −1.10 (− 1.76, − 0.28) | −1.03 (− 1.93, − 0.41) | 0.979 b |